At what testosterone threshold should TRT begin?

Bhasin 2018 (Endocrine Society Guideline): TRT indicated if total T <264 ng/dL on 2 repeated morning measurements (8-10am) + clinical hypogonadism symptoms (low libido, fatigue, depression, lean mass loss, erectile dysfunction, gynecomastia). More conservative Franco-European threshold: persistent <300 ng/dL + symptoms. Hackett 2017 (BSSM UK) also suggests a combined clinical threshold (T + symptoms). Important: an isolated reading of 280 ng/dL without symptoms does NOT justify TRT. Differential diagnosis mandatory (obesity, sleep, medications, depression).

Lifelong TRT or reversible?

For primary hypogonadism (non-functional testicles — Klinefelter, trauma, post-chemo): lifelong TRT. For secondary hypogonadism (failing hypothalamic axis): reversibility possible if treatable cause (morbid obesity, opioids, etc.). For post-AAS ASIH in young user: attempt natural recovery with Lipshultz protocol (Rahnema 2014) before permanent TRT. Once TRT started, stopping requires a classic PCT and HPG recovery period of 3-6 months, without guarantee of complete recovery if TRT >2 years.

What long-term cardiovascular effects of TRT?

Debated question. The Calof 2005 meta-analysis and several observational studies suggested a modest increase in CV events in certain profiles. The TRAVERSE study (Lincoff 2023, NEJM) — reference RCT with 5246 hypogonadal men at CV risk — demonstrated TRT non-inferiority vs placebo over 33 months (HR 0.96 for MACE events). Saad 2017 (12-year registry) shows metabolic benefits. Conclusion: TRT in hypogonadal men with medical supervision does not increase CV risk; the only concerning factor remains erythrocytosis (hematocrit >54%) to monitor.

Is AI (anastrozole) always needed under TRT?

No. Bhasin 2018 does NOT recommend systematic AI. The majority of TRT patients at physiological dose (100-150 mg/wk) have E2 in the physiological range without AI. AI only if: (1) documented ultra-sensitive E2 >50-60 pg/mL, AND (2) clinical symptoms (evolving gynecomastia, marked retention, paradoxical libido drop). AI overdose is more dangerous than absence of AI: E2 <20 pg/mL causes severe symptoms (Finkelstein 2013, Burnett-Bowie 2009 — bone density). Anastrozole 0.25 mg E3D max at initiation, titrate.

Elevated hematocrit on TRT: what to do?

Erythrocytosis (hematocrit >54%) is the most frequent TRT adverse effect (Coviello 2008, Bachman 2014: mechanism via hepcidin suppression). Algorithm: (1) Hematocrit 50-54%: quarterly monitoring, hydration +1L/d, avoid high dose. (2) Hematocrit 54-57%: therapeutic phlebotomy (450 ml bloodletting, 1-3x/yr), reduce TRT dose by 20%. (3) Hematocrit >57%: immediate phlebotomy + dose revision. (4) Recurrence despite adjustments: consider switching to transdermal gel or SC microdosing (Bhasin 2018, Hackett 2017).

TRT and fertility: compatible?

Exogenous testosterone suppresses LH/FSH and spermatogenesis — incompatible with fertility without precautions. Solutions: (1) Adding hCG 500 IU 2x/wk during TRT maintains spermatogenesis (Coviello 2005, Depenbusch 2002). (2) Adding FSH (Menopur, Gonal-F) if hCG insufficient in certain patients. (3) TRT pause 3-6 months pre-conception + classic PCT + hCG (Wenker 2015). (4) Sperm storage before starting TRT in men of reproductive age. Reference: Crosnoe 2013, Wenker 2015, Bhasin 2018.

SC or IM route: what difference?

Several recent studies (2017-2023) suggest the subcutaneous (SC) route with insulin needle 30G x 8 mm gives serum levels comparable to IM, with slightly slower absorption (~80-85% of IM AUC) and less discomfort. SC advantages: painless, more sites available (abdomen, thighs, glutes), no intravascular injection risk. SC disadvantages: volumes >0.5 ml sometimes uncomfortable, possible indurations with poor rotation. In 2026, SC route is widely adopted in modern TRT, especially for microdoses. Bhasin 2018 recognizes SC as acceptable alternative.

How to monitor long-term TRT?

Recommended bloodwork (Bhasin 2018, Hackett 2017): Initial (before start) — total + free T, LH, FSH, E2, SHBG, CBC, lipids, PSA if >40, hematocrit, creatinine, ALT/AST, BMI, blood pressure. At 3 months post-start: total T (trough), E2, hematocrit, lipids. At 6 months: same + PSA if >40. At 12 months and annually: complete bloodwork + bone densitometry every 2-3 years, polysomnography if sleep apnea symptoms. Particular monitoring: hematocrit (target <54%), PSA (target variation <0.75 ng/mL/yr), stable blood pressure.

Best TRT (testosterone replacement) protocols in 2026 — 10 schemes compared

Q: Lifelong TRT or reversible?

For primary hypogonadism (non-functional testicles — Klinefelter, trauma, post-chemo): lifelong TRT. For secondary hypogonadism (failing hypothalamic axis): reversibility possible if treatable cause (morbid obesity, opioids, etc.). For post-AAS ASIH in young user: attempt natural recovery with Lipshultz protocol (Rahnema 2014) before permanent TRT. Once TRT started, stopping requires a classic PCT and HPG recovery period of 3-6 months, without guarantee of complete recovery if TRT >2 years.

Q: Elevated hematocrit on TRT: what to do?

Erythrocytosis (hematocrit >54%) is the most frequent TRT adverse effect (Coviello 2008, Bachman 2014: mechanism via hepcidin suppression). Algorithm: (1) Hematocrit 50-54%: quarterly monitoring, hydration +1L/d, avoid high dose. (2) Hematocrit 54-57%: therapeutic phlebotomy (450 ml bloodletting, 1-3x/yr), reduce TRT dose by 20%. (3) Hematocrit >57%: immediate phlebotomy + dose revision. (4) Recurrence despite adjustments: consider switching to transdermal gel or SC microdosing (Bhasin 2018, Hackett 2017).

Methodology

Rankings based on 4 weighted criteria for TRT. (1) Hormonal stability: amplitude of serum testosterone fluctuations between two injections ('peak-to-trough'), ideally < 200 ng/dL spread to minimize cyclical symptoms (mood swings, energy fluctuations, libido). (2) Long-term safety profile: cardiovascular effects (Calof 2005 meta-analysis, TRAVERSE study Lincoff 2023), hematocrit (Coviello 2008, Bachman 2014), PSA and prostate (Bhasin 2018), lipid profile. (3) Accessibility: medical supervision (prescribed TRT vs self-administered), product availability, annual cost, logistical complexity. (4) Fit with profile: age (young user with ASIH does not have the same goals as a >50-year-old man with primary hypogonadism), fertility desire, comorbidities, injection preference. Primary sources: Bhasin 2018 (Endocrine Society Guideline), Lincoff 2023 (TRAVERSE NEJM), Saad 2017 (long-term TRT registry), Calof 2005 (TRT adverse events meta), Coviello 2008 (hematocrit dose-response), Hackett 2017 (BSSM UK).

1. Test cypionate 140 mg/wk (2 inj/wk) — the modern gold standard
The most widely adopted TRT protocol in 2026, validated by the Endocrine Society (Bhasin 2018) and BSSM UK (Hackett 2017). Testosterone cypionate (half-life ~8 d) in two subcutaneous or intramuscular injections (70 mg Monday, 70 mg Thursday). Stable serum level reached in 4-6 weeks, peak-to-trough fluctuations ~150-200 ng/dL. Therapeutic target: total T 600-900 ng/dL, E2 25-45 pg/mL.
Dose / Duration
Test cypionate (or enanthate equivalent) 140 mg/wk split into 2 injections (Mon 70 mg / Thu 70 mg). SC or IM. Evaluation at W6 (total + free T, E2, hematocrit) and adjustment by 20 mg increments. No duration — continuous protocol for life.
Target audience
Men 30-70 with confirmed hypogonadism (total T <300 ng/dL on 2 morning measurements + symptoms), confirmed post-AAS ASIH, fertility desire managed separately (+hCG). Ideal medical framework.
Pros
- + Optimal hormonal stability — fluctuations <200 ng/dL
- + Validated by Endocrine Society (Bhasin 2018)
- + Moderate logistical comfort (2 injections/wk)
- + Fertility compatibility with added hCG
- + Moderate cost with prescription (~$80-200/yr generic)
Cons
- − Lifelong injections
- − Hematocrit to monitor (>54% = phlebotomy indicated)
- − PSA to monitor >50 years old
- − Supply sometimes constrained in some regions
- − Long-term cardiovascular effects to monitor
2. Test cypionate 100 mg/wk (3 inj/wk or EOD) — maximum stability
'Ultra-stable' variant: split into 3 injections/wk (~33 mg each) or daily subcutaneous injection (~14 mg/d). Reduces serum fluctuations to <100 ng/dL peak-to-trough — useful for patients sensitive to variations (mood swings, fluctuating libido). Particularly suited to subcutaneous microdoses.
Dose / Duration
Test cypionate 100-120 mg/wk split into 3 inj (Mon/Wed/Fri) or daily injection 14-17 mg/d SC. Insulin needle 30G x 8 mm. Evaluation at W6-W8.
Target audience
TRT patients sensitive to hormonal fluctuations (cyclical mood between injections), optimizer users seeking maximum stability, low-SHBG profiles. Good option in case of E2 intolerance on 2 inj/wk.
Pros
- + Minimal serum fluctuations (<100 ng/dL)
- + Reduces aromatization by peak smoothing
- + Painless insulin needle
- + Compatible with daily activity (5 min/day)
- + Often better E2 profile at low dose
Cons
- − Daily or 3 inj/wk logistics
- − Long-term adherence sometimes difficult
- − Manual preparation (drawing through fine needle)
- − No demonstrated clinical benefit vs 2 inj/wk in the majority
- − Injection site revascularization cycle to manage
3. Test undecanoate (Nebido) 1000 mg/12 wk IM — long-acting TRT
Test undecanoate IM (Nebido in Europe, Aveed in the USA): very long ester (half-life ~21 d), injection every 10-14 weeks after loading dose. Correct serum stability if timing respected. Behre 1999 (phase 1) and Saad 2017 (12-year registry) document a good long-term profile. Rare but documented risk of pulmonary oil microembolism (POME) — slow injection mandatory.
Dose / Duration
Test undecanoate 1000 mg IM. Loading dose: W0 then W6. Maintenance: every 10-14 wk based on trough levels. Deep gluteal injection, very slow (>2 min) to limit POME.
Target audience
TRT patients preferring minimal injection frequency, men >50 with stable hypogonadism, untroubled cardiovascular and hematological profile. Ideal for patients reluctant to self-inject.
Pros
- + Maximum logistical comfort (4-5 inj/year only)
- + Correct serum stability over 10-12 wk
- + Validated in Europe (Nebido MA), USA (Aveed)
- + Excellent long-term adherence
- + Saad 2017 documents beneficial effects on body composition, metabolic
Cons
- − POME risk (rare but documented, <1% — Behre 1999)
- − High cost (~$50-80/injection, ~$250-400/yr)
- − Deep IM injection, sometimes painful
- − Difficulty fine-tuning (single 1000 mg dose)
- − Variable availability by country
4. Transdermal gel (Testogel/Androgel) 50-80 mg/d — non-injection TRT
Skin gel applied daily (shoulder, arm, abdomen). Stable serum concentrations if correctly applied, without peak or valley — the most 'physiological' profile of all TRT protocols. Bhasin 2018 mentions the gel as a first-line option in certain indications. Main drawback: risk of skin transfer to partner or children (precautions to observe).
Dose / Duration
Testogel sachet 50 mg/d (5 g 1% gel) or pump 30-80 mg/d (Androgel 1.62%). Morning application after shower on dry skin. 4-6 wk delay to reach stability.
Target audience
Injection-phobic patients, men living alone (limits transfer), elderly patients with mild hypogonadism, desire for ultra-physiological profile. Not suited to families with young children or partners.
Pros
- + No injection — facilitated adherence
- + Most physiological serum profile (circadian rhythm preserved)
- + No supraphysiological peak
- + Validated in pharmacy (MA Europe and USA)
- + Rapid stop possible (24-48h clearance)
Cons
- − Transfer risk to partner/children (Bhasin 2018 warnings)
- − Variable absorption by individuals (5-15% bioavailability)
- − High cost (~$600-1500/yr)
- − Limited effect in 20-30% of patients (poor absorbers)
- − Constraining daily application
5. Test cypionate + hCG (140 mg + 500 IU 2x/wk) — the fertility-preserved TRT
Gold standard protocol for TRT in men of reproductive age. Exogenous testosterone suppresses HPG axis and spermatogenesis; adding hCG 500 IU 2x/wk maintains Leydig cells and intratesticular spermatogenesis (Coviello 2005, Depenbusch 2002). Wenker 2015 documents hCG + TRT combination for long-term fertility preservation.
Dose / Duration
Test cypionate 140 mg/wk in 2 inj + hCG 500 IU 2x/wk (Mon/Thu, same days as test or alternating). Evaluation at W8: testosterone, sperm analysis if parental project, E2, testicular volume.
Target audience
Men 25-50 on TRT with fertility desire (present or future), partners in pregnancy project, men valuing testicular volume. Standard recommended in all young users.
Pros
- + Documented fertility preservation (Wenker 2015)
- + Testicular volume preserved
- + Psychological comfort (visible testicles)
- + Allows parental project without TRT interruption
- + Physiological mechanism (mimics endogenous LH)
Cons
- − Additional cost (~$150-300/yr for hCG)
- − Logistics of additional injections
- − Risk of E2 increase (mini-aromatization of stimulated Leydig)
- − Black-market hCG: variable quality
- − Leydig desensitization possible if hCG too high
6. Physiological-dose "ultra-low" TRT 80-100 mg/wk — the subliminal TRT
Minimal-dose TRT targeting the low end of normal range (450-600 ng/dL total T) in patients sensitive to supraphysiological effects or with borderline hematocrit. Preserves subjective benefits (libido, energy, mood) while minimizing cardiovascular risks and erythrocytosis (Coviello 2008: dose-dependent hematocrit).
Dose / Duration
Test cypionate 80-100 mg/wk in 2 inj (40-50 mg Mon/Thu). Target total T 500-700 ng/dL, E2 20-35 pg/mL. Evaluation at W6-W8.
Target audience
Elderly patients (>60), cardiovascular history, borderline baseline hematocrit (>50%), seeking subjective improvement without supraphysiological peak. Ideal for 'health' TRT rather than 'performance'.
Pros
- + Stable hematocrit, minimal erythrocytosis risk
- + Preserved lipid profile
- + Moderate aromatization (often without AI)
- + Lowest annual cost
- + Suited to elderly or cardiovascular-borderline patients
Cons
- − Subjective benefits sometimes sub-optimal
- − Not suited to patients with very high SHBG
- − Less favorable body composition
- − Energy and libido sometimes insufficient
- − Requires precise individual adjustment
7. "Optimized" TRT 200 mg/wk — the "top of range" TRT
TRT at the high end of physiological normal (900-1100 ng/dL total T), seeking maximum subjective benefits and body composition. Off-label (Bhasin 2018 targets 500-900 ng/dL), but practiced in private clinics (US, Europe). Requires rigorous monitoring: hematocrit, lipids, PSA, blood pressure. Long-term cardiovascular risk to weigh (Lincoff 2023 TRAVERSE).
Dose / Duration
Test cypionate 200 mg/wk in 2 inj (100 mg Mon/Thu). Target total T 900-1100 ng/dL. AI often needed (anastrozole 0.25-0.5 mg/wk). Quarterly bloodwork.
Target audience
Bodybuilders transitioning to 'cruise' post-AAS cycles, anti-aging optimizers accepting risk profile, men 35-55 in good baseline cardiovascular health. Serious medical supervision required.
Pros
- + Maximum subjective benefits (libido, energy, mood)
- + Significantly improved body composition
- + Notable physical performance
- + Marked subjective anti-aging effect
- + Compatibility with bodybuilding "cruise"
Cons
- − Strictly off-label (target T > recommendations)
- − Hematocrit often >52% — recurrent phlebotomies
- − Degraded lipid profile
- − AI frequently needed — risk of E2 too low
- − Higher cost
8. TRT + anastrozole 0.25 mg E3D — the E2-controlled TRT
Standard TRT (140 mg/wk) with addition of low-dose anastrozole for rapid-aromatizer patients (E2 > 50 pg/mL at physiological dose). Anastrozole blocks aromatase and lowers E2; dose to titrate precisely because E2 too low (<20 pg/mL) causes severe symptoms (libido loss, joint pain, cognitive disturbances — Finkelstein 2013).
Dose / Duration
Test cypionate 140 mg/wk + Anastrozole 0.25-0.5 mg E3D or 1 mg/wk. Ultra-sensitive E2 evaluation at W4 then W8. Target E2 25-40 pg/mL.
Target audience
TRT patients with excessive aromatization (E2 >50 at physio dose), gynecomastia history, marked water retention under TRT. Not first-line — only if documented E2 out of target.
Pros
- + Aromatization control in rapid aromatizers
- + Reduces gynecomastia and retention
- + Improves subjective TRT tolerance
- + Allows more generous TRT doses
- + Mauras 2009 documents anastrozole safety
Cons
- − Risk of E2 too low if AI overdose (Burnett-Bowie 2009: bone density)
- − Low E2 symptoms: libido drop, joint pain, depression
- − Expensive ultra-sensitive E2 bloodwork not always available
- − AI unnecessary in majority of physiological-dose TRT patients
- − Requires fine adjustment
9. "hCG mono" TRT (1000-2000 IU 2x/wk) — TRT without exogenous testosterone
Alternative to exogenous TRT for men with secondary hypogonadism (low LH/FSH, functional testicular axis). hCG directly stimulates Leydig steroidogenesis without additional hypothalamic suppression. Allows preservation of spermatogenesis and testicular volume. Liu 2002 documents spermatogenesis induction by hCG alone or combined. Suited to a specific subgroup of patients.
Dose / Duration
hCG 1000-2000 IU 2x/wk SC (Mon/Thu). Evaluation of total T at W6 (target 500-800 ng/dL). Adjustment by 250 IU increments. E2 bloodwork important.
Target audience
Men with secondary hypogonadism (functional testicular axis, low LH/FSH), strong desire to preserve fertility, post-AAS ASIH in young user in long recovery. Endocrinologist evaluation required first.
Pros
- + No exogenous testosterone — HPG axis preserved
- + Spermatogenesis maintained (often improved)
- + Testicular volume increased
- + Alternative for secondary hypogonadism
- + Direct physiological mechanism
Cons
- − High annual cost (~$600-1500 depending on dose)
- − Long-term Leydig desensitization possible
- − E2 often elevated (stimulated Leydig also produce E2)
- − Not suited to primary hypogonadism (non-functional testicles)
- − Limited long-term studies vs classic TRT
10. TRT "microdosing" daily SC 15-20 mg/d — modern optimized TRT
Modern trend: daily subcutaneous microdoses (15-20 mg test cypionate with insulin needle) for minimal serum fluctuations (<80 ng/dL) and SHBG preserved. Several recent studies (~2020-2024) suggest a better hormonal profile on SHBG, E2 and subjective symptomatology vs less frequent injections. Practice still being standardized but widely adopted in private clinics.
Dose / Duration
Test cypionate 15-20 mg/d SC (insulin needle 30G x 8 mm). Site rotation (abdomen, thighs, glutes). Target stable total T 600-900 ng/dL.
Target audience
TRT patients seeking maximum optimization, anti-aging optimizers, users sensitive to hormonal fluctuations, low-SHBG profiles, young men on long-term TRT.
Pros
- + Near-zero serum fluctuations
- + SHBG better preserved vs large doses
- + E2 often more stable and lower
- + Painless (insulin needle)
- + Rotation feasible on 6-8 sites
Cons
- − Daily commitment (5 min/day)
- − Manual preparation of small doses (precision required)
- − No RCT yet comparing to 2 inj/wk
- − Long-term adherence sometimes difficult
- − Skin indurations possible with poor rotation

Final comparison

Protocol	Stability	Fertility	Logistics	Cost/yr
Test cyp 140 mg (2x/wk)	Very good	Compromised (without hCG)	Simple	$80-200
Test cyp 100 mg (3x/wk or EOD)	Excellent	Compromised (without hCG)	Medium	$80-180
Test undecanoate (Nebido)	Good	Compromised (without hCG)	Very simple (4-5 inj/yr)	$250-400
Transdermal gel	Excellent	Compromised	Daily	$600-1500
Test cyp + hCG	Very good	Preserved	Medium	$300-500
Ultra-low TRT 80 mg	Good	Reduced	Simple	$60-150
Optimized TRT 200 mg	Good	Very compromised	Simple	$150-300
TRT + AI	Good	Compromised	Medium	$120-250
hCG mono	Medium	Preserved	Medium	$600-1500
Microdosing daily SC	Maximum	Compromised (without hCG)	Daily	$80-200

FAQ

At what testosterone threshold should TRT begin?: Bhasin 2018 (Endocrine Society Guideline): TRT indicated if total T <264 ng/dL on 2 repeated morning measurements (8-10am) + clinical hypogonadism symptoms (low libido, fatigue, depression, lean mass loss, erectile dysfunction, gynecomastia). More conservative Franco-European threshold: persistent <300 ng/dL + symptoms. Hackett 2017 (BSSM UK) also suggests a combined clinical threshold (T + symptoms). Important: an isolated reading of 280 ng/dL without symptoms does NOT justify TRT. Differential diagnosis mandatory (obesity, sleep, medications, depression).
Lifelong TRT or reversible?: For primary hypogonadism (non-functional testicles — Klinefelter, trauma, post-chemo): lifelong TRT. For secondary hypogonadism (failing hypothalamic axis): reversibility possible if treatable cause (morbid obesity, opioids, etc.). For post-AAS ASIH in young user: attempt natural recovery with Lipshultz protocol (Rahnema 2014) before permanent TRT. Once TRT started, stopping requires a classic PCT and HPG recovery period of 3-6 months, without guarantee of complete recovery if TRT >2 years.
What long-term cardiovascular effects of TRT?: Debated question. The Calof 2005 meta-analysis and several observational studies suggested a modest increase in CV events in certain profiles. The TRAVERSE study (Lincoff 2023, NEJM) — reference RCT with 5246 hypogonadal men at CV risk — demonstrated TRT non-inferiority vs placebo over 33 months (HR 0.96 for MACE events). Saad 2017 (12-year registry) shows metabolic benefits. Conclusion: TRT in hypogonadal men with medical supervision does not increase CV risk; the only concerning factor remains erythrocytosis (hematocrit >54%) to monitor.
Is AI (anastrozole) always needed under TRT?: No. Bhasin 2018 does NOT recommend systematic AI. The majority of TRT patients at physiological dose (100-150 mg/wk) have E2 in the physiological range without AI. AI only if: (1) documented ultra-sensitive E2 >50-60 pg/mL, AND (2) clinical symptoms (evolving gynecomastia, marked retention, paradoxical libido drop). AI overdose is more dangerous than absence of AI: E2 <20 pg/mL causes severe symptoms (Finkelstein 2013, Burnett-Bowie 2009 — bone density). Anastrozole 0.25 mg E3D max at initiation, titrate.
Elevated hematocrit on TRT: what to do?: Erythrocytosis (hematocrit >54%) is the most frequent TRT adverse effect (Coviello 2008, Bachman 2014: mechanism via hepcidin suppression). Algorithm: (1) Hematocrit 50-54%: quarterly monitoring, hydration +1L/d, avoid high dose. (2) Hematocrit 54-57%: therapeutic phlebotomy (450 ml bloodletting, 1-3x/yr), reduce TRT dose by 20%. (3) Hematocrit >57%: immediate phlebotomy + dose revision. (4) Recurrence despite adjustments: consider switching to transdermal gel or SC microdosing (Bhasin 2018, Hackett 2017).
TRT and fertility: compatible?: Exogenous testosterone suppresses LH/FSH and spermatogenesis — incompatible with fertility without precautions. Solutions: (1) Adding hCG 500 IU 2x/wk during TRT maintains spermatogenesis (Coviello 2005, Depenbusch 2002). (2) Adding FSH (Menopur, Gonal-F) if hCG insufficient in certain patients. (3) TRT pause 3-6 months pre-conception + classic PCT + hCG (Wenker 2015). (4) Sperm storage before starting TRT in men of reproductive age. Reference: Crosnoe 2013, Wenker 2015, Bhasin 2018.
SC or IM route: what difference?: Several recent studies (2017-2023) suggest the subcutaneous (SC) route with insulin needle 30G x 8 mm gives serum levels comparable to IM, with slightly slower absorption (~80-85% of IM AUC) and less discomfort. SC advantages: painless, more sites available (abdomen, thighs, glutes), no intravascular injection risk. SC disadvantages: volumes >0.5 ml sometimes uncomfortable, possible indurations with poor rotation. In 2026, SC route is widely adopted in modern TRT, especially for microdoses. Bhasin 2018 recognizes SC as acceptable alternative.
How to monitor long-term TRT?: Recommended bloodwork (Bhasin 2018, Hackett 2017): Initial (before start) — total + free T, LH, FSH, E2, SHBG, CBC, lipids, PSA if >40, hematocrit, creatinine, ALT/AST, BMI, blood pressure. At 3 months post-start: total T (trough), E2, hematocrit, lipids. At 6 months: same + PSA if >40. At 12 months and annually: complete bloodwork + bone densitometry every 2-3 years, polysomnography if sleep apnea symptoms. Particular monitoring: hematocrit (target <54%), PSA (target variation <0.75 ng/mL/yr), stable blood pressure.

Best TRT (testosterone replacement) protocols in 2026 — 10 schemes compared

Methodology

1. Test cypionate 140 mg/wk (2 inj/wk) — the modern gold standard

The most widely adopted TRT protocol in 2026, validated by the Endocrine Society (Bhasin 2018) and BSSM UK (Hackett 2017). Testosterone cypionate (half-life ~8 d) in two subcutaneous or intramuscular injections (70 mg Monday, 70 mg Thursday). Stable serum level reached in 4-6 weeks, peak-to-trough fluctuations ~150-200 ng/dL. Therapeutic target: total T 600-900 ng/dL, E2 25-45 pg/mL.

Dose / Duration

Test cypionate (or enanthate equivalent) 140 mg/wk split into 2 injections (Mon 70 mg / Thu 70 mg). SC or IM. Evaluation at W6 (total + free T, E2, hematocrit) and adjustment by 20 mg increments. No duration — continuous protocol for life.

Target audience

Men 30-70 with confirmed hypogonadism (total T <300 ng/dL on 2 morning measurements + symptoms), confirmed post-AAS ASIH, fertility desire managed separately (+hCG). Ideal medical framework.

Pros

+ Optimal hormonal stability — fluctuations <200 ng/dL
+ Validated by Endocrine Society (Bhasin 2018)
+ Moderate logistical comfort (2 injections/wk)
+ Fertility compatibility with added hCG
+ Moderate cost with prescription (~$80-200/yr generic)

Cons

− Lifelong injections
− Hematocrit to monitor (>54% = phlebotomy indicated)
− PSA to monitor >50 years old
− Supply sometimes constrained in some regions
− Long-term cardiovascular effects to monitor

2. Test cypionate 100 mg/wk (3 inj/wk or EOD) — maximum stability

'Ultra-stable' variant: split into 3 injections/wk (~33 mg each) or daily subcutaneous injection (~14 mg/d). Reduces serum fluctuations to <100 ng/dL peak-to-trough — useful for patients sensitive to variations (mood swings, fluctuating libido). Particularly suited to subcutaneous microdoses.

Dose / Duration

Test cypionate 100-120 mg/wk split into 3 inj (Mon/Wed/Fri) or daily injection 14-17 mg/d SC. Insulin needle 30G x 8 mm. Evaluation at W6-W8.

Target audience

TRT patients sensitive to hormonal fluctuations (cyclical mood between injections), optimizer users seeking maximum stability, low-SHBG profiles. Good option in case of E2 intolerance on 2 inj/wk.

Pros

+ Minimal serum fluctuations (<100 ng/dL)
+ Reduces aromatization by peak smoothing
+ Painless insulin needle
+ Compatible with daily activity (5 min/day)
+ Often better E2 profile at low dose

Cons

− Daily or 3 inj/wk logistics
− Long-term adherence sometimes difficult
− Manual preparation (drawing through fine needle)
− No demonstrated clinical benefit vs 2 inj/wk in the majority
− Injection site revascularization cycle to manage

3. Test undecanoate (Nebido) 1000 mg/12 wk IM — long-acting TRT

Test undecanoate IM (Nebido in Europe, Aveed in the USA): very long ester (half-life ~21 d), injection every 10-14 weeks after loading dose. Correct serum stability if timing respected. Behre 1999 (phase 1) and Saad 2017 (12-year registry) document a good long-term profile. Rare but documented risk of pulmonary oil microembolism (POME) — slow injection mandatory.

Dose / Duration

Test undecanoate 1000 mg IM. Loading dose: W0 then W6. Maintenance: every 10-14 wk based on trough levels. Deep gluteal injection, very slow (>2 min) to limit POME.

Target audience

TRT patients preferring minimal injection frequency, men >50 with stable hypogonadism, untroubled cardiovascular and hematological profile. Ideal for patients reluctant to self-inject.

Pros

+ Maximum logistical comfort (4-5 inj/year only)
+ Correct serum stability over 10-12 wk
+ Validated in Europe (Nebido MA), USA (Aveed)
+ Excellent long-term adherence
+ Saad 2017 documents beneficial effects on body composition, metabolic

Cons

− POME risk (rare but documented, <1% — Behre 1999)
− High cost (~$50-80/injection, ~$250-400/yr)
− Deep IM injection, sometimes painful
− Difficulty fine-tuning (single 1000 mg dose)
− Variable availability by country

4. Transdermal gel (Testogel/Androgel) 50-80 mg/d — non-injection TRT

Skin gel applied daily (shoulder, arm, abdomen). Stable serum concentrations if correctly applied, without peak or valley — the most 'physiological' profile of all TRT protocols. Bhasin 2018 mentions the gel as a first-line option in certain indications. Main drawback: risk of skin transfer to partner or children (precautions to observe).

Dose / Duration

Testogel sachet 50 mg/d (5 g 1% gel) or pump 30-80 mg/d (Androgel 1.62%). Morning application after shower on dry skin. 4-6 wk delay to reach stability.

Target audience

Injection-phobic patients, men living alone (limits transfer), elderly patients with mild hypogonadism, desire for ultra-physiological profile. Not suited to families with young children or partners.

Pros

+ No injection — facilitated adherence
+ Most physiological serum profile (circadian rhythm preserved)
+ No supraphysiological peak
+ Validated in pharmacy (MA Europe and USA)
+ Rapid stop possible (24-48h clearance)

Cons

− Transfer risk to partner/children (Bhasin 2018 warnings)
− Variable absorption by individuals (5-15% bioavailability)
− High cost (~$600-1500/yr)
− Limited effect in 20-30% of patients (poor absorbers)
− Constraining daily application

5. Test cypionate + hCG (140 mg + 500 IU 2x/wk) — the fertility-preserved TRT

Gold standard protocol for TRT in men of reproductive age. Exogenous testosterone suppresses HPG axis and spermatogenesis; adding hCG 500 IU 2x/wk maintains Leydig cells and intratesticular spermatogenesis (Coviello 2005, Depenbusch 2002). Wenker 2015 documents hCG + TRT combination for long-term fertility preservation.

Dose / Duration

Test cypionate 140 mg/wk in 2 inj + hCG 500 IU 2x/wk (Mon/Thu, same days as test or alternating). Evaluation at W8: testosterone, sperm analysis if parental project, E2, testicular volume.

Target audience

Men 25-50 on TRT with fertility desire (present or future), partners in pregnancy project, men valuing testicular volume. Standard recommended in all young users.

Pros

+ Documented fertility preservation (Wenker 2015)
+ Testicular volume preserved
+ Psychological comfort (visible testicles)
+ Allows parental project without TRT interruption
+ Physiological mechanism (mimics endogenous LH)

Cons

− Additional cost (~$150-300/yr for hCG)
− Logistics of additional injections
− Risk of E2 increase (mini-aromatization of stimulated Leydig)
− Black-market hCG: variable quality
− Leydig desensitization possible if hCG too high

6. Physiological-dose "ultra-low" TRT 80-100 mg/wk — the subliminal TRT

Minimal-dose TRT targeting the low end of normal range (450-600 ng/dL total T) in patients sensitive to supraphysiological effects or with borderline hematocrit. Preserves subjective benefits (libido, energy, mood) while minimizing cardiovascular risks and erythrocytosis (Coviello 2008: dose-dependent hematocrit).

Dose / Duration

Test cypionate 80-100 mg/wk in 2 inj (40-50 mg Mon/Thu). Target total T 500-700 ng/dL, E2 20-35 pg/mL. Evaluation at W6-W8.

Target audience

Elderly patients (>60), cardiovascular history, borderline baseline hematocrit (>50%), seeking subjective improvement without supraphysiological peak. Ideal for 'health' TRT rather than 'performance'.

Pros

+ Stable hematocrit, minimal erythrocytosis risk
+ Preserved lipid profile
+ Moderate aromatization (often without AI)
+ Lowest annual cost
+ Suited to elderly or cardiovascular-borderline patients

Cons

− Subjective benefits sometimes sub-optimal
− Not suited to patients with very high SHBG
− Less favorable body composition
− Energy and libido sometimes insufficient
− Requires precise individual adjustment

7. "Optimized" TRT 200 mg/wk — the "top of range" TRT

TRT at the high end of physiological normal (900-1100 ng/dL total T), seeking maximum subjective benefits and body composition. Off-label (Bhasin 2018 targets 500-900 ng/dL), but practiced in private clinics (US, Europe). Requires rigorous monitoring: hematocrit, lipids, PSA, blood pressure. Long-term cardiovascular risk to weigh (Lincoff 2023 TRAVERSE).

Dose / Duration

Test cypionate 200 mg/wk in 2 inj (100 mg Mon/Thu). Target total T 900-1100 ng/dL. AI often needed (anastrozole 0.25-0.5 mg/wk). Quarterly bloodwork.

Target audience

Bodybuilders transitioning to 'cruise' post-AAS cycles, anti-aging optimizers accepting risk profile, men 35-55 in good baseline cardiovascular health. Serious medical supervision required.

Pros

+ Maximum subjective benefits (libido, energy, mood)
+ Significantly improved body composition
+ Notable physical performance
+ Marked subjective anti-aging effect
+ Compatibility with bodybuilding "cruise"

Cons

− Strictly off-label (target T > recommendations)
− Hematocrit often >52% — recurrent phlebotomies
− Degraded lipid profile
− AI frequently needed — risk of E2 too low
− Higher cost

8. TRT + anastrozole 0.25 mg E3D — the E2-controlled TRT

Standard TRT (140 mg/wk) with addition of low-dose anastrozole for rapid-aromatizer patients (E2 > 50 pg/mL at physiological dose). Anastrozole blocks aromatase and lowers E2; dose to titrate precisely because E2 too low (<20 pg/mL) causes severe symptoms (libido loss, joint pain, cognitive disturbances — Finkelstein 2013).

Dose / Duration

Test cypionate 140 mg/wk + Anastrozole 0.25-0.5 mg E3D or 1 mg/wk. Ultra-sensitive E2 evaluation at W4 then W8. Target E2 25-40 pg/mL.

Target audience

TRT patients with excessive aromatization (E2 >50 at physio dose), gynecomastia history, marked water retention under TRT. Not first-line — only if documented E2 out of target.

Pros

+ Aromatization control in rapid aromatizers
+ Reduces gynecomastia and retention
+ Improves subjective TRT tolerance
+ Allows more generous TRT doses
+ Mauras 2009 documents anastrozole safety

Cons

− Risk of E2 too low if AI overdose (Burnett-Bowie 2009: bone density)
− Low E2 symptoms: libido drop, joint pain, depression
− Expensive ultra-sensitive E2 bloodwork not always available
− AI unnecessary in majority of physiological-dose TRT patients
− Requires fine adjustment

9. "hCG mono" TRT (1000-2000 IU 2x/wk) — TRT without exogenous testosterone

Alternative to exogenous TRT for men with secondary hypogonadism (low LH/FSH, functional testicular axis). hCG directly stimulates Leydig steroidogenesis without additional hypothalamic suppression. Allows preservation of spermatogenesis and testicular volume. Liu 2002 documents spermatogenesis induction by hCG alone or combined. Suited to a specific subgroup of patients.

Dose / Duration

hCG 1000-2000 IU 2x/wk SC (Mon/Thu). Evaluation of total T at W6 (target 500-800 ng/dL). Adjustment by 250 IU increments. E2 bloodwork important.

Target audience

Men with secondary hypogonadism (functional testicular axis, low LH/FSH), strong desire to preserve fertility, post-AAS ASIH in young user in long recovery. Endocrinologist evaluation required first.

Pros

+ No exogenous testosterone — HPG axis preserved
+ Spermatogenesis maintained (often improved)
+ Testicular volume increased
+ Alternative for secondary hypogonadism
+ Direct physiological mechanism

Cons

− High annual cost (~$600-1500 depending on dose)
− Long-term Leydig desensitization possible
− E2 often elevated (stimulated Leydig also produce E2)
− Not suited to primary hypogonadism (non-functional testicles)
− Limited long-term studies vs classic TRT

10. TRT "microdosing" daily SC 15-20 mg/d — modern optimized TRT

Modern trend: daily subcutaneous microdoses (15-20 mg test cypionate with insulin needle) for minimal serum fluctuations (<80 ng/dL) and SHBG preserved. Several recent studies (~2020-2024) suggest a better hormonal profile on SHBG, E2 and subjective symptomatology vs less frequent injections. Practice still being standardized but widely adopted in private clinics.

Dose / Duration

Test cypionate 15-20 mg/d SC (insulin needle 30G x 8 mm). Site rotation (abdomen, thighs, glutes). Target stable total T 600-900 ng/dL.

Target audience

TRT patients seeking maximum optimization, anti-aging optimizers, users sensitive to hormonal fluctuations, low-SHBG profiles, young men on long-term TRT.

Pros

+ Near-zero serum fluctuations
+ SHBG better preserved vs large doses
+ E2 often more stable and lower
+ Painless (insulin needle)
+ Rotation feasible on 6-8 sites

Cons

− Daily commitment (5 min/day)
− Manual preparation of small doses (precision required)
− No RCT yet comparing to 2 inj/wk
− Long-term adherence sometimes difficult
− Skin indurations possible with poor rotation

Final comparison

Protocol	Stability	Fertility	Logistics	Cost/yr
Test cyp 140 mg (2x/wk)	Very good	Compromised (without hCG)	Simple	$80-200
Test cyp 100 mg (3x/wk or EOD)	Excellent	Compromised (without hCG)	Medium	$80-180
Test undecanoate (Nebido)	Good	Compromised (without hCG)	Very simple (4-5 inj/yr)	$250-400
Transdermal gel	Excellent	Compromised	Daily	$600-1500
Test cyp + hCG	Very good	Preserved	Medium	$300-500
Ultra-low TRT 80 mg	Good	Reduced	Simple	$60-150
Optimized TRT 200 mg	Good	Very compromised	Simple	$150-300
TRT + AI	Good	Compromised	Medium	$120-250
hCG mono	Medium	Preserved	Medium	$600-1500
Microdosing daily SC	Maximum	Compromised (without hCG)	Daily	$80-200

FAQ

At what testosterone threshold should TRT begin?: Bhasin 2018 (Endocrine Society Guideline): TRT indicated if total T <264 ng/dL on 2 repeated morning measurements (8-10am) + clinical hypogonadism symptoms (low libido, fatigue, depression, lean mass loss, erectile dysfunction, gynecomastia). More conservative Franco-European threshold: persistent <300 ng/dL + symptoms. Hackett 2017 (BSSM UK) also suggests a combined clinical threshold (T + symptoms). Important: an isolated reading of 280 ng/dL without symptoms does NOT justify TRT. Differential diagnosis mandatory (obesity, sleep, medications, depression).
Lifelong TRT or reversible?: For primary hypogonadism (non-functional testicles — Klinefelter, trauma, post-chemo): lifelong TRT. For secondary hypogonadism (failing hypothalamic axis): reversibility possible if treatable cause (morbid obesity, opioids, etc.). For post-AAS ASIH in young user: attempt natural recovery with Lipshultz protocol (Rahnema 2014) before permanent TRT. Once TRT started, stopping requires a classic PCT and HPG recovery period of 3-6 months, without guarantee of complete recovery if TRT >2 years.
What long-term cardiovascular effects of TRT?: Debated question. The Calof 2005 meta-analysis and several observational studies suggested a modest increase in CV events in certain profiles. The TRAVERSE study (Lincoff 2023, NEJM) — reference RCT with 5246 hypogonadal men at CV risk — demonstrated TRT non-inferiority vs placebo over 33 months (HR 0.96 for MACE events). Saad 2017 (12-year registry) shows metabolic benefits. Conclusion: TRT in hypogonadal men with medical supervision does not increase CV risk; the only concerning factor remains erythrocytosis (hematocrit >54%) to monitor.
Is AI (anastrozole) always needed under TRT?: No. Bhasin 2018 does NOT recommend systematic AI. The majority of TRT patients at physiological dose (100-150 mg/wk) have E2 in the physiological range without AI. AI only if: (1) documented ultra-sensitive E2 >50-60 pg/mL, AND (2) clinical symptoms (evolving gynecomastia, marked retention, paradoxical libido drop). AI overdose is more dangerous than absence of AI: E2 <20 pg/mL causes severe symptoms (Finkelstein 2013, Burnett-Bowie 2009 — bone density). Anastrozole 0.25 mg E3D max at initiation, titrate.
Elevated hematocrit on TRT: what to do?: Erythrocytosis (hematocrit >54%) is the most frequent TRT adverse effect (Coviello 2008, Bachman 2014: mechanism via hepcidin suppression). Algorithm: (1) Hematocrit 50-54%: quarterly monitoring, hydration +1L/d, avoid high dose. (2) Hematocrit 54-57%: therapeutic phlebotomy (450 ml bloodletting, 1-3x/yr), reduce TRT dose by 20%. (3) Hematocrit >57%: immediate phlebotomy + dose revision. (4) Recurrence despite adjustments: consider switching to transdermal gel or SC microdosing (Bhasin 2018, Hackett 2017).
TRT and fertility: compatible?: Exogenous testosterone suppresses LH/FSH and spermatogenesis — incompatible with fertility without precautions. Solutions: (1) Adding hCG 500 IU 2x/wk during TRT maintains spermatogenesis (Coviello 2005, Depenbusch 2002). (2) Adding FSH (Menopur, Gonal-F) if hCG insufficient in certain patients. (3) TRT pause 3-6 months pre-conception + classic PCT + hCG (Wenker 2015). (4) Sperm storage before starting TRT in men of reproductive age. Reference: Crosnoe 2013, Wenker 2015, Bhasin 2018.
SC or IM route: what difference?: Several recent studies (2017-2023) suggest the subcutaneous (SC) route with insulin needle 30G x 8 mm gives serum levels comparable to IM, with slightly slower absorption (~80-85% of IM AUC) and less discomfort. SC advantages: painless, more sites available (abdomen, thighs, glutes), no intravascular injection risk. SC disadvantages: volumes >0.5 ml sometimes uncomfortable, possible indurations with poor rotation. In 2026, SC route is widely adopted in modern TRT, especially for microdoses. Bhasin 2018 recognizes SC as acceptable alternative.
How to monitor long-term TRT?: Recommended bloodwork (Bhasin 2018, Hackett 2017): Initial (before start) — total + free T, LH, FSH, E2, SHBG, CBC, lipids, PSA if >40, hematocrit, creatinine, ALT/AST, BMI, blood pressure. At 3 months post-start: total T (trough), E2, hematocrit, lipids. At 6 months: same + PSA if >40. At 12 months and annually: complete bloodwork + bone densitometry every 2-3 years, polysomnography if sleep apnea symptoms. Particular monitoring: hematocrit (target <54%), PSA (target variation <0.75 ng/mL/yr), stable blood pressure.